Who are 5-fluorouracil,leucovorin,panitumumab's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): FOLFOX/ FOLFIRI with panitumumab.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/5-fluorouracil-leucovorin-panitumumab.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

5-fluorouracil,leucovorin,panitumumab — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

5-fluorouracil,leucovorin,panitumumab (5-fluorouracil,leucovorin,panitumumab) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Chemotherapy combination with EGFR inhibitor. Area: Oncology.

phase 2 Chemotherapy combination with EGFR inhibitor Thymidylate synthase (5-FU), EGFR (panitumumab) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

5-fluorouracil,leucovorin,panitumumab (5-fluorouracil,leucovorin,panitumumab) — Fondazione IRCCS Istituto Nazionale dei Tumori, Milano. This combination uses 5-fluorouracil and leucovorin as chemotherapy agents to inhibit thymidylate synthase and enhance fluorouracil cytotoxicity, while panitumumab blocks EGFR signaling to prevent tumor cell growth and survival.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
5-fluorouracil,leucovorin,panitumumab TARGET	5-fluorouracil,leucovorin,panitumumab	Fondazione IRCCS Istituto Nazionale dei Tumori, Milano	phase 2	Chemotherapy combination with EGFR inhibitor	Thymidylate synthase (5-FU), EGFR (panitumumab)
FOLFOX/ FOLFIRI with panitumumab	FOLFOX/ FOLFIRI with panitumumab	Dutch Colorectal Cancer Group	phase 3	Chemotherapy combination with EGFR inhibitor	EGFR (panitumumab component)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Chemotherapy combination with EGFR inhibitor class)

Dutch Colorectal Cancer Group · 1 drug in this class
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). 5-fluorouracil,leucovorin,panitumumab — Competitive Intelligence Brief. https://druglandscape.com/ci/5-fluorouracil-leucovorin-panitumumab. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab